BiotechTube

TAF + TDF + TAF Placebo + TDF Placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HBV

Conditions

HBV, Chronic HBV Infection

Trial Timeline

Jun 19, 2015 → Sep 18, 2023

NCT ID
NCT02836236

About TAF + TDF + TAF Placebo + TDF Placebo

TAF + TDF + TAF Placebo + TDF Placebo is a phase 3 stage product being developed by Gilead Sciences for HBV. The current trial status is completed. This product is registered under clinical trial identifier NCT02836236. Target conditions include HBV, Chronic HBV Infection.

What happened to similar drugs?

1 of 4 similar drugs in HBV were approved

Approved (1) Terminated (0) Active (3)
✅Telbivudine + Enecavir + AdefovirNovartisApproved
🔄B/F/TAF + Placebo to match DTG + Placebo to match F/TDF + DTG + F/TDF + Placebo to match B/F/TAFGilead SciencesPhase 3
🔄TAF + TDF + TAF Placebo + TDF PlaceboGilead SciencesPhase 3
🔄Tenofovir disoproxil fumarate (TDF) + PlaceboGilead SciencesPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT02979613Phase 3Completed
NCT02836236Phase 3Completed
NCT02836249Phase 3Completed
NCT01940341Phase 3Completed
NCT01940471Phase 3Completed

Competing Products

8 competing products in HBV

See all competitors
ProductCompanyStageHype Score
Telbivudine + Enecavir + AdefovirNovartisApproved
39
B/F/TAF + Placebo to match DTG + Placebo to match F/TDF + DTG + F/TDF + Placebo to match B/F/TAFGilead SciencesPhase 3
40
TAF + TDF + TAF Placebo + TDF PlaceboGilead SciencesPhase 3
40
Tenofovir disoproxil fumarate (TDF) + PlaceboGilead SciencesPhase 3
40
GS-4774 + OAV RegimenGilead SciencesPhase 2
35
EDP-514 + PlaceboEnanta PharmaceuticalsPhase 1
19
EDP-514 + PlaceboEnanta PharmaceuticalsPhase 1
19
PBGENE-HBVPrecision BioSciencesPre-clinical
23